Table 32Study, participant, and intervention characteristics for KQ 7

Author, YearStudy DesignArm, nDrug Name, DoseAge (Years) Mean±SDMale, n (%)BMI Mean±SDWeight Mean±SDPrior History of VTE, n (%)
Freeman A, 2012151Prospective cohort studyFixed-dose Enoxaparin, 11Enoxaparin, 40 mg daily45.5 ± 7.22 (18.2)63.4 ± 11.6175.0 ± 39.9NR
Lower-dose Enoxaparin, 9Enoxaparin, 0.4 mg/kg daily43.8 ± 15.76 (66.7)60.7 ± 12.4171.2 ± 42.8NR
Higher-dose Enoxaparin, 11Enoxaparin 0.5 mg/kg daily42.7 ± 12.33 (27.3)61.3 ± 12.2179.6 ± 30.3NR
Kucher, N., 2005150Randomized Controlled TrialDalteparin, 558DalteparinNRNRNRNRNR
Placebo, 560PlaceboNRNRNRNRNR

BMI = body mass index; NR = not reported; VTE = venous thromboembolism

*

Median reported.

From: Results

Cover of Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations
Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet].
Comparative Effectiveness Reviews, No. 116.
Singh S, Haut ER, Brotman DJ, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.